BIO-TECHNE ANNOUNCES BIOTHERAPEUTIC CHARACTERIZATION STRATEGIC CO-MARKETING AND CO-PROMOTION AGREEMENT
Bio-Techne (NASDAQ: TECH) has announced a strategic co-marketing and co-promotion agreement with Waters to enhance biotherapeutic characterization and development processes. The partnership combines Bio-Techne's MauriceFlex™ System for charge separation with Waters' BioAccord™ LC-MS System for liquid chromatography mass spectrometry.
The collaboration has already yielded joint activities in late 2024, including an application note, webinar, and presentations at major conferences such as CASSS MS, Festival of Biologics, and PEGS EU. Scientists from both companies are currently working on analyzing additional biomolecule classes, with plans to showcase results at upcoming scientific conferences through various formats including application notes and webinars.
Bio-Techne (NASDAQ: TECH) ha annunciato un accordo strategico di co-marketing e co-promozione con Waters per migliorare i processi di caratterizzazione e sviluppo bioterapeutici. La partnership combina il sistema MauriceFlex™ di Bio-Techne per la separazione delle cariche con il sistema BioAccord™ LC-MS di Waters per la spettrometria di massa in cromatografia liquida.
La collaborazione ha già prodotto attività congiunte nella fine del 2024, tra cui una nota applicativa, un webinar e presentazioni a conferenze importanti come CASSS MS, Festival of Biologics e PEGS UE. Gli scienziati di entrambe le aziende stanno attualmente lavorando all'analisi di ulteriori classi di biomolecole, con piani per presentare i risultati a prossime conferenze scientifiche attraverso vari formati, incluse note applicative e webinar.
Bio-Techne (NASDAQ: TECH) ha anunciado un acuerdo estratégico de co-marketing y co-promoción con Waters para mejorar los procesos de caracterización y desarrollo bioterapéutico. La asociación combina el sistema MauriceFlex™ de Bio-Techne para la separación de cargas con el sistema BioAccord™ LC-MS de Waters para la espectrometría de masas en cromatografía líquida.
La colaboración ya ha generado actividades conjuntas a finales de 2024, incluyendo una nota de aplicación, un seminario web y presentaciones en conferencias importantes como CASSS MS, Festival of Biologics y PEGS UE. Los científicos de ambas empresas están trabajando actualmente en el análisis de clases adicionales de biomoléculas, con planes para mostrar los resultados en próximas conferencias científicas a través de varios formatos, incluyendo notas de aplicación y seminarios web.
Bio-Techne (NASDAQ: TECH)는 생물 의약품 특성 분석 및 개발 프로세스를 향상시키기 위해 Waters와 전략적 공동 마케팅 및 공동 프로모션 계약을 체결했다고 발표했습니다. 이 파트너십은 Bio-Techne의 전하 분리를 위한 MauriceFlex™ 시스템과 Waters의 액체 크로마토그래피 질량 분석을 위한 BioAccord™ LC-MS 시스템을 결합합니다.
이 협력은 이미 2024년 말에 공동 활동을 생성했으며, 여기에는 응용 노트, 웨비나 및 CASSS MS, Festival of Biologics 및 PEGS EU와 같은 주요 회의에서의 발표가 포함됩니다. 두 회사의 과학자들은 현재 추가 생체 분자군 분석 작업을 하고 있으며, 응용 노트 및 웨비나와 같은 다양한 형식을 통해 다가오는 과학 회의에서 결과를 보여줄 계획입니다.
Bio-Techne (NASDAQ: TECH) a annoncé un accord stratégique de co-marketing et de co-promotion avec Waters pour améliorer la caractérisation et le développement des biothérapies. Le partenariat combine le système MauriceFlex™ de Bio-Techne pour la séparation des charges avec le système BioAccord™ LC-MS de Waters pour la spectrométrie de masse en chromatographie liquide.
La collaboration a déjà donné lieu à des activités conjointes à la fin de 2024, notamment une note d’application, un webinaire et des présentations lors de grandes conférences telles que CASSS MS, le Festival of Biologics et PEGS UE. Des scientifiques des deux entreprises travaillent actuellement à l'analyse de classes supplémentaires de biomolécules, avec des projets de présentation des résultats lors de conférences scientifiques à venir via divers formats, y compris des notes d'application et des webinaires.
Bio-Techne (NASDAQ: TECH) hat eine strategische Co-Marketing- und Co-Promotion-Vereinbarung mit Waters bekannt gegeben, um die Charakterisierung und Entwicklung biotherapeutischer Prozesse zu verbessern. Die Partnerschaft kombiniert das MauriceFlex™-System von Bio-Techne zur Ladungstrennung mit dem BioAccord™ LC-MS-System von Waters zur Flüssigchromatographie-Massenspektrometrie.
Die Zusammenarbeit hat bereits Ende 2024 gemeinsame Aktivitäten hervorgebracht, darunter ein Anwendungsdokument, ein Webinar und Präsentationen auf wichtigen Konferenzen wie CASSS MS, Festival of Biologics und PEGS EU. Wissenschaftler beider Unternehmen arbeiten derzeit an der Analyse zusätzlicher Biomoleklassten und planen, die Ergebnisse bei kommenden wissenschaftlichen Konferenzen in verschiedenen Formaten, einschließlich Anwendungsdokumenten und Webinaren, zu präsentieren.
- Strategic partnership with Waters enhances product offering in biotherapeutic characterization
- Expansion of market reach through combined expertise and technologies
- Active collaboration demonstrated through multiple scientific presentations and publications
- None.
Insights
The co-marketing agreement between Bio-Techne and Waters represents an incremental business development rather than a substantial financial catalyst. While the partnership combines Bio-Techne's MauriceFlex™ System with Waters' BioAccord™ LC-MS System, creating potential workflow optimizations in biotherapeutic characterization, this is primarily a marketing collaboration without immediate revenue implications.
The key value proposition lies in the potential for future market penetration through combined sales efforts and technical integration. However, the announcement focuses on past marketing activities (conferences, webinars) and future promotional plans rather than concrete business metrics or financial commitments. For Bio-Techne, with a market cap of
The collaboration may enhance Bio-Techne's competitive position in the biotherapeutic characterization space by offering more comprehensive solutions to customers, but the impact will likely be gradual and dependent on successful execution of joint marketing initiatives.
From a technical perspective, the integration of Bio-Techne's charge separation technology with Waters' mass spectrometry capabilities addresses a significant workflow challenge in biotherapeutic development. The MauriceFlex™ System's charge variant analysis capabilities, when combined with the BioAccord™ LC-MS System, could potentially reduce analysis time and improve characterization accuracy for complex biologics.
However, this collaboration appears focused on marketing synergies rather than technological innovation or product development. The emphasis on application notes, webinars and conference presentations suggests a promotional strategy aimed at increasing market awareness rather than developing new integrated solutions. While valuable for customer education and market visibility, such initiatives typically yield modest returns in the highly competitive biotech tools sector.
Scientists and commercial team members from both companies participated in several joint activities in October and November 2024, including the publication of an application note, a webinar, poster presentations, and talks at key conferences including CASSS MS, Festival of Biologics and PEGS EU, and in-person talks at two Bio-Techne User Group Meetings in
"We are thrilled to see how these new workflows are accelerating biotherapeutic characterization in biopharma labs," said Will Geist, President of the Protein Sciences Segment at Bio-Techne. "Our goal is to continue offering innovative solutions that empower scientists, streamline workflows, and help bring life-saving therapies to market faster."
Explore Bio-Techne's automated biotherapeutic characterization platforms here.
Learn about Waters innovative analytical solutions here.
About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated approximately
Contact: David Clair, Vice President, Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-4416
BioAccord is a trademark of Waters Technologies Corporation.
View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-announces-biotherapeutic-characterization-strategic-co-marketing-and-co-promotion-agreement-302335808.html
SOURCE Bio-Techne Corporation
FAQ
What is the purpose of Bio-Techne's (TECH) partnership with Waters ?
What joint activities have Bio-Techne (TECH) and Waters conducted in 2024?
How will the Bio-Techne (TECH) and Waters partnership benefit biotherapeutic development?
What are the future plans for the Bio-Techne (TECH) and Waters collaboration?
